{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:06Z","timestamp":1793889786716,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01935-8","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:56:04Z","timestamp":1736164564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)"],"prefix":"10.1186","volume":"26","author":[{"given":"Luigi Francesco","family":"Iannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Vaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sebastianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Casillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Silvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Dalla","family":"Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiarugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Antonio","family":"Montisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Prudenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mampreso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Avino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Battistini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Maria","family":"Piella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocenzo","family":"Rainero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Icco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Italian Headache Registry (RICe) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mascarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bolchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Saporito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Grazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marcinn\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Garascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Boscain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Burgalassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Trimboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Doretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"issue":"19","key":"1935_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Ashina","year":"2020","unstructured":"Ashina AM (2020) Migraine. N Engl J Med 383(19):1866\u20131876","journal-title":"N Engl J Med"},{"issue":"3","key":"1935_CR2","first-page":"597","volume":"27","author":"J Ailani","year":"2021","unstructured":"Ailani J (2021) Acute migraine treatment. Continuum (Minneap Minn) 27(3):597\u2013612","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"1935_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/papr.12461","volume":"17","author":"G Affaitati","year":"2017","unstructured":"Affaitati G, Martelletti P, Lopopolo M, Tana C, Massimini F, Cipollone F et al (2017) Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract 17(3):392\u2013401","journal-title":"Pain Pract"},{"issue":"1","key":"1935_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-023-01652-8","volume":"24","author":"G Vaghi","year":"2023","unstructured":"Vaghi G, De Icco R, Tassorelli C, Goadsby PJ, Vicente-Herrero T, de la Torre ER (2023) Who cares about migraine? Pathways and hurdles in the European region - access to care III. J Headache Pain 24(1):120","journal-title":"J Headache Pain"},{"issue":"3","key":"1935_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","volume":"81","author":"CL Petersen","year":"2024","unstructured":"Petersen CL, Hougaard A, Gaist D, Hallas J (2024) Risk of Stroke and myocardial infarction among initiators of triptans. JAMA Neurol 81(3):248\u2013254","journal-title":"JAMA Neurol"},{"issue":"4","key":"1935_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/0333102413508661","volume":"34","author":"K Thorlund","year":"2014","unstructured":"Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E et al (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34(4):258\u2013267","journal-title":"Cephalalgia"},{"issue":"10","key":"1935_CR7","doi-asserted-by":"publisher","first-page":"e2128544","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP, Liang CS, Chang CM, Yang CC, Shih PH, Yau YC et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1935_CR8","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s10072-024-07493-w","volume":"45","author":"S Sacco","year":"2024","unstructured":"Sacco S, Di Ciaccio S, Di Virgilio R, Pegoraro V, Ornello R (2024) Acute treatment of migraine: quantifying the unmet need through real-world data in Italy. Neurol Sci 45(9):4427\u20134435","journal-title":"Neurol Sci"},{"issue":"S2","key":"1935_CR9","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1111\/j.1526-4610.1999.00006.x","volume":"39","author":"RB Lipton","year":"1999","unstructured":"Lipton RB, Stewart WF (1999) Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39(S2):S20\u2013S6","journal-title":"Headache"},{"issue":"1","key":"1935_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C et al (2023) Medication overuse headache. Nat Rev Dis Primers 9(1):5","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"1935_CR11","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","volume":"43","author":"C Altamura","year":"2022","unstructured":"Altamura C, Brunelli N, Marcosano M, Fofi L, Vernieri F (2022) Gepants - a long way to cure: a narrative review. Neurol Sci 43(9):5697\u20135708","journal-title":"Neurol Sci"},{"key":"1935_CR12","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind. Placebo-Controlled Trial J Pain Res 17:2431\u20132441","journal-title":"Placebo-Controlled Trial J Pain Res"},{"issue":"1","key":"1935_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells12010143","volume":"12","author":"AR Pavelic","year":"2022","unstructured":"Pavelic AR, Wober C, Riederer F, Zebenholzer K (2022) Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells 12(1):143","journal-title":"Cells"},{"issue":"6","key":"1935_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/14737175.2022.2091435","volume":"22","author":"AA Argyriou","year":"2022","unstructured":"Argyriou AA, Mantovani E, Mitsikostas DD, Vikelis M, Tamburin S (2022) A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Expert Rev Neurother 22(6):469\u2013488","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"1935_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and meta-analysis of anti-cgrp monoclonal antibodies: predicting response. Pharmaceuticals (Basel) 16(7):934","journal-title":"\u00a0Pharmaceuticals (Basel)"},{"issue":"3","key":"1935_CR16","doi-asserted-by":"publisher","first-page":"333102423115216","DOI":"10.1177\/03331024231152169","volume":"43","author":"R Messina","year":"2023","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):3331024231152169","journal-title":"Cephalalgia"},{"issue":"8","key":"1935_CR17","doi-asserted-by":"publisher","first-page":"333102424125266","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666","journal-title":"Cephalalgia"},{"issue":"6","key":"1935_CR18","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/jcm11061656","volume":"11","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Villar-Martinez MD, Goadsby PJ (2022) New generation gepants: migraine acute and preventive medications. J Clin Med 11(6):1656","journal-title":"J Clin Med"},{"issue":"10200","key":"1935_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745","journal-title":"Lancet"},{"issue":"2","key":"1935_CR20","doi-asserted-by":"publisher","first-page":"333102422114168","DOI":"10.1177\/03331024221141686","volume":"43","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L\u2019Italien G et al (2023) Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia 43(2):3331024221141686","journal-title":"Cephalalgia"},{"issue":"2","key":"1935_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149","journal-title":"N Engl J Med"},{"issue":"7","key":"1935_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40265-020-01301-3","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Rimegepant: first approval. Drugs 80(7):741\u2013746","journal-title":"Drugs"},{"issue":"12","key":"1935_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40263-023-01050-3","volume":"37","author":"V Caponnetto","year":"2023","unstructured":"Caponnetto V, Russo A, Silvestro M, Tessitore A, De Icco R, Vaghi G et al (2023) Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine: a prospective multicenter cohort study. CNS Drugs 37(12):1069\u20131080","journal-title":"CNS Drugs"},{"key":"1935_CR24","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders. 3rd Ed. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"3","key":"1935_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia 31(3):357\u2013367","journal-title":"Cephalalgia"},{"issue":"1","key":"1935_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN (2000) Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 88(1):41\u201352","journal-title":"Pain"},{"issue":"4","key":"1935_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1526-4610.2006.00403.x","volume":"46","author":"SG Kilminster","year":"2006","unstructured":"Kilminster SG, Dowson AJ, Tepper SJ, Baos V, Baudet F, D\u2019Amico D (2006) Reliability, validity, and clinical utility of the migraine-ACT questionnaire. Headache 46(4):553\u2013562","journal-title":"Headache"},{"issue":"6","key":"1935_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22(6):476\u2013484","journal-title":"Lancet Neurol"},{"issue":"1","key":"1935_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10194-019-1066-0","volume":"20","author":"AP Andreou","year":"2019","unstructured":"Andreou AP, Edvinsson L (2019) Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 20(1):117","journal-title":"J Headache Pain"},{"issue":"8","key":"1935_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455\u2013464","journal-title":"Nat Rev Neurol"},{"key":"1935_CR31","doi-asserted-by":"publisher","first-page":"174480691876769","DOI":"10.1177\/1744806918767697","volume":"14","author":"M Su","year":"2018","unstructured":"Su M, Yu S (2018) Chronic migraine: a process of dysmodulation and sensitization. Mol Pain 14:1744806918767697","journal-title":"Mol Pain"},{"issue":"9","key":"1935_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102420938652","volume":"40","author":"E Navratilova","year":"2020","unstructured":"Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F (2020) Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 40(9):892\u2013902","journal-title":"Cephalalgia"},{"key":"1935_CR33","doi-asserted-by":"publisher","first-page":"251581632210755","DOI":"10.1177\/25158163221075596","volume":"5","author":"G L'Italien","year":"2022","unstructured":"L\u2019Italien G, Popoff E, Johnston K, McGrath D, Conway CM, Powell L et al (2022) Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: results from a long-term, open-label study. Cephalalgia Rep 5:25158163221075596","journal-title":"Cephalalgia Rep"},{"issue":"4","key":"1935_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","volume":"28","author":"PJ Goadsby","year":"2008","unstructured":"Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H et al (2008) Early vs. non-early intervention in acute migraine-\u2019Act when Mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28(4):383\u201391","journal-title":"Cephalalgia"},{"issue":"2","key":"1935_CR35","doi-asserted-by":"publisher","first-page":"333102422114377","DOI":"10.1177\/03331024221143773","volume":"43","author":"I de Boer","year":"2023","unstructured":"de Boer I, Verhagen IE, Souza MNP, Ashina M (2023) Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia 43(2):3331024221143773","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01935-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01935-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01935-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:01:53Z","timestamp":1736164913000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01935-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01935-8","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved as a part of the <i>Registro Italiano Cefalee (RICe)<\/i> study by the local Ethics Committee (CEAVC Studio RICe, 14591_oss and subsequent amendments 2022\u2013609; 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"LFI received fees and Honoraria for advisory boards, speaker panels from Teva, Eli Lilly, Lundbeck, Pfizer and AbbVie. GV received personal fees from Lundbeck; M.S has received speaker honoraria from Novartis, Teva, and Lilly; AR has received speaker honoraria from Allergan, Lilly, Novartis, Biogen, and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session); SC received honoraria for speaker panels from Teva and Novartis; MPP received speaker honoraria and advisory board participation from Abbvie, Idorsia, Eli-Lilly, Novartis, Pfizer, TEVA; RO reports personal fees and non-financial support from Allergan-AbbVie, Eli Lilly, Novartis, Pfizer, and Teva; RDI reports personal fees and non-financial support from Eli-Lilly, AbbVie, Pfizer, Lundbeck, and TEVA. Other authors have no conflicting interests on this specific study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}